Who are 5-fluoro-2-deoxycytidine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xeloda, Fudr, Folic Acid, Folferi and celecoxib, Irinotecan, 5FU, leucovorin, chemotherapy of mFOLFOX6 or FOLFIRI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/5-fluoro-2-deoxycytidine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

5-fluoro-2-deoxycytidine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

5-fluoro-2-deoxycytidine (5-fluoro-2-deoxycytidine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nucleoside analog. Area: Oncology.

phase 1 Nucleoside analog Thymidylate synthase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

5-fluoro-2-deoxycytidine (5-fluoro-2-deoxycytidine) — City of Hope Medical Center. Inhibits thymidylate synthase

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
5-fluoro-2-deoxycytidine TARGET	5-fluoro-2-deoxycytidine	City of Hope Medical Center	phase 1	Nucleoside analog	Thymidylate synthase
Xeloda	capecitabine	Cheplapharm	marketed	Nucleoside Metabolic Inhibitor [EPC]	Thymidylate synthase	1998-01-01
Fudr	FLOXURIDINE		marketed	Antimetabolite [EPC]	Thymidylate synthase	1970-01-01
Folic Acid	FOLIC ACID	Pfizer	marketed	Vitamin C [EPC]	Thymidylate synthase	1946-01-01
Folferi and celecoxib	Folferi and celecoxib	Sherief Abd-Elsalam	marketed	Chemotherapy combination with COX-2 inhibitor	Topoisomerase I (irinotecan), thymidylate synthase (fluorouracil), COX-2
Irinotecan, 5FU, leucovorin	Irinotecan, 5FU, leucovorin	Asan Medical Center	marketed	Chemotherapy combination (topoisomerase I inhibitor + antimetabolite)	Topoisomerase I; thymidylate synthase
chemotherapy of mFOLFOX6 or FOLFIRI	chemotherapy of mFOLFOX6 or FOLFIRI	Xu jianmin	marketed	Combination chemotherapy regimen	Thymidylate synthase (5-FU), DNA topoisomerase I (irinotecan), DNA (oxaliplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nucleoside analog class)

Third Affiliated Hospital, Sun Yat-Sen University · 2 drugs in this class
Actuate Therapeutics Inc. · 2 drugs in this class
City of Hope Medical Center · 1 drug in this class
Cooperative Study Group A for Hematology · 1 drug in this class
Genzyme, a Sanofi Company · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
Innovent Biologics (Suzhou) Co. Ltd. · 1 drug in this class
Osaka Medical Center for Cancer and Cardiovascular Diseases · 1 drug in this class
Tanabe Pharma Corporation · 1 drug in this class
The Methodist Hospital Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). 5-fluoro-2-deoxycytidine — Competitive Intelligence Brief. https://druglandscape.com/ci/5-fluoro-2-deoxycytidine. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab